February 5, 2018

—The small size of the flexible, bandage-like pump would reduce barriers to using automated insulin-delivery systems—

New York, February 5, 2018—JDRF, the leading global organization funding type 1 diabetes (T1D) research, and Cam Med LLC, a developer of microfluidic-based drug delivery technologies, announced a new Industry Development and Discovery Partnership today to develop a user-centric insulin pump for next-generation artificial pancreas systems.

This funding commitment from Breakthrough T1D will enable Cam Med to further the development of its innovative Evopump, an ultra-thin and flexible, bandage-like patch pump.

Since Breakthrough T1D launched the Artificial Pancreas Project more than a decade ago, significant progress has been made in automating insulin delivery.  However, the bulkiness of  automated insulin delivery devices remains a challenge and may be a factor inhibiting wide-scale adoption, especially in children where skin ”real estate” is at a premium. The goal of this collaboration is to accelerate the development of Cam Med’s conformable and small-footprint Evopump, which would represent a substantial improvement over existing delivery systems for both pediatric and adult users.

Jaime Giraldo, Ph.D., Breakthrough T1D Program Scientist, Research, said, “Breakthrough T1D is excited to partner with Cam Med on improving insulin delivery hardware. The Evopump represents the type of miniaturized and user-centric design that could substantially reduce the burden of living with type 1 diabetes and remove obstacles preventing some people, particularly children, from using devices that could improve their glucose management.”

“The Evopump’s unique multi-reservoir, electrochemically-actuated design is a game-changer not just in terms of its user-friendly, bandage-like form, but also because it enables the Evopump to be manufactured at a much lower cost than conventional pumps,” notes Dr. Zhifei Ge, CTO of Cam Med and co-inventor of the Evopump. Adds Larry Alberts, CEO of Cam Med, “This partnership with Breakthrough T1D enables Cam Med to accelerate the development and commercialization of the Evopump, and we’re looking forward to it becoming the core delivery platform for future AP systems.”

T1D is an autoimmune disease that occurs when a person’s pancreas stops producing insulin, the hormone that controls blood-sugar levels. T1D develops when the insulin-producing pancreatic beta cells are mistakenly destroyed by the body’s immune system. T1D must be managed with the lifelong use of insulin—either via injection or insulin pump.

ABOUT Breakthrough T1D
Breakthrough T1D is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, Breakthrough T1D has invested more than $2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF.

About Cam Med
Cam Med is a medical device startup applying microfluidics to develop drug delivery technologies that enable substantial improvements in the daily lives of users. Cam Med Is developing the Evopump, the first truly bandage-like, ultra-thin and flexible patch pump for delivering one or multiple injectable drugs.  An automatically-filled, actively-controllable, wearable and disposable device, the Evopump could greatly improve compliance for the tens of millions of people who face challenging regimens Involving frequent of injections of medication.  Founded in 2014, Cam Med is based at the Massachusetts Medical Device Development Center (M2D2) in Lowell, Massachusetts.  For more information on Cam Med, please visit www.myevopump.com.

Media Contact:
Kristy Evans